Dianthus Therapeutics DNTH Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dianthus Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dianthus Therapeutics's cash & equivalents?
- Dianthus Therapeutics (DNTH) reported cash & equivalents of $627.67M in Q1 2026.
- How has Dianthus Therapeutics's cash & equivalents changed year-over-year?
- Dianthus Therapeutics's cash & equivalents increased by 6104.7% year-over-year, from $10.12M to $627.67M.
- What is the long-term trend for Dianthus Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Dianthus Therapeutics's cash & equivalents has grown at a -2.6% compound annual growth rate (CAGR), from $58.15M to $51.09M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.